Parkman Healthcare Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $20.9M | Sell |
166,010
-2,372
| -1% | -$298K | 2.4% | 11 |
|
|
2025
Q1 | $18.6M | Buy |
168,382
+52,655
| +45% | +$5.82M | 2.21% | 13 |
|
|
2024
Q4 | $15.8M | Sell |
115,727
-14,113
| -11% | -$1.93M | 2.1% | 15 |
|
|
2024
Q3 | $15M | Buy |
129,840
+14,670
| +13% | +$1.69M | 1.91% | 17 |
|
|
2024
Q2 | $15.9M | Sell |
115,170
-16,781
| -13% | -$2.31M | 2.12% | 12 |
|
|
2024
Q1 | $18.2M | Sell |
131,951
-8,165
| -6% | -$1.13M | 2.23% | 11 |
|
|
2023
Q4 | $18.5M | Buy |
140,116
+56,271
| +67% | +$7.41M | 2.6% | 10 |
|
|
2023
Q3 | $9.43M | Sell |
83,845
-55,890
| -40% | -$6.29M | 1.73% | 15 |
|
|
2023
Q2 | $13.2M | Sell |
139,735
-78,103
| -36% | -$7.37M | 2.28% | 13 |
|
|
2023
Q1 | $22M | Buy |
217,838
+101,505
| +87% | +$10.3M | 4.8% | 2 |
|
|
2022
Q4 | $13.9M | Sell |
116,333
-1,067
| -0.9% | -$127K | 3.7% | 4 |
|
|
2022
Q3 | $12.5M | Buy |
117,400
+31,811
| +37% | +$3.38M | 3.55% | 5 |
|
|
2022
Q2 | $8.34M | Buy |
85,589
+22,355
| +35% | +$2.18M | 3.07% | 9 |
|
|
2022
Q1 | $5.93M | Buy |
+63,234
| New | +$5.93M | 1.73% | 20 |
|
|
2020
Q4 | – | Sell |
-132,544
| Closed | -$12.7M | – | 93 |
|
|
2020
Q3 | $12.7M | Buy |
132,544
+11,018
| +9% | +$1.06M | 3.37% | 3 |
|
|
2020
Q2 | $14.8M | Sell |
121,526
-7,000
| -5% | -$854K | 4.18% | 1 |
|
|
2020
Q1 | $11.1M | Sell |
128,526
-26,899
| -17% | -$2.33M | 5.16% | 2 |
|
|
2019
Q4 | $16.7M | Buy |
+155,425
| New | +$16.7M | 4.82% | 2 |
|